AnalyzeDirect

Iwan E. Bennett¹, Kathryn M. Field³, Christopher M. Hovens¹, Bradford A. Moffat², Mark A. Rosenthal³, Katharine Drummond^1,4, Andrew H. Kaye^1,4, Andrew P. Morokoff^1,4. Early perfusion MRI predicts survival outcome in patients with recurrent glioblastoma treated with bevacizumab and carboplatin Journal of Neuro-Oncology. November 28 2016.

Publication Date
November 2016

How Analyze was Used
“Using Analyze 10.0, tumor regions of interest (ROIs) were created from contrast-enhancing regions on T1-weighted sequences (T1 + C ROI) and hyperintense regions on FLAIR sequences (FLAIR ROI).”

Keywords
Bevacizumab, Glioblastoma, DSC, MRI, rCBV, Perfusion

Author Affiliation(s)
¹Department of Surgery, The Royal Melbourne Hospital, The University of Melbourne, Parkville, Australia
²Department of Radiology, The Royal Melbourne Hospital, The University of Melbourne, Parkville, Australia
³Department of Medical Oncology, The Royal Melbourne Hospital, Parkville, Australia
⁴Department of Neurosurgery, The Royal Melbourne Hospital, Parkville, Australia

Tags: Bevacizumab, DSC, Glioblastoma, MRI, Perfusion, rCBV